These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 1590680)

  • 1. Multiple-dose pharmacokinetics of cefprozil and its impact on intestinal flora of volunteers.
    Lode H; Müller C; Borner K; Nord CE; Koeppe P
    Antimicrob Agents Chemother; 1992 Jan; 36(1):144-9. PubMed ID: 1590680
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multiple dose pharmacokinetics, safety, and effects on faecal microflora, of cefepime in healthy volunteers.
    Bächer K; Schaeffer M; Lode H; Nord CE; Borner K; Koeppe P
    J Antimicrob Chemother; 1992 Sep; 30(3):365-75. PubMed ID: 1452502
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Absolute bioavailability of cefprozil after oral administration in beagles.
    Barbhaiya RH; Wang L; Shyu WC; Pittman KA
    Antimicrob Agents Chemother; 1992 Mar; 36(3):687-9. PubMed ID: 1622187
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I study of multiple-dose cefprozil and comparison with cefaclor.
    Barbhaiya RH; Shukla UA; Gleason CR; Shyu WC; Wilber RB; Martin RR; Pittman KA
    Antimicrob Agents Chemother; 1990 Jun; 34(6):1198-203. PubMed ID: 2393281
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Excretion of cefprozil into human breast milk.
    Shyu WC; Shah VR; Campbell DA; Venitz J; Jaganathan V; Pittman KA; Wilber RB; Barbhaiya RH
    Antimicrob Agents Chemother; 1992 May; 36(5):938-41. PubMed ID: 1510416
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ertapenem pharmacokinetics and impact on intestinal microflora, in comparison to those of ceftriaxone, after multiple dosing in male and female volunteers.
    Pletz MW; Rau M; Bulitta J; De Roux A; Burkhardt O; Kruse G; Kurowski M; Nord CE; Lode H
    Antimicrob Agents Chemother; 2004 Oct; 48(10):3765-72. PubMed ID: 15388432
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multiple-dose pharmacokinetics of sparfloxacin and its influence on fecal flora.
    Ritz M; Lode H; Fassbender M; Borner K; Koeppe P; Nord CE
    Antimicrob Agents Chemother; 1994 Mar; 38(3):455-9. PubMed ID: 8203837
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of antacid on the bioavailability of cefprozil.
    Shyu WC; Wilber RB; Pittman KA; Barbhaiya RH
    Antimicrob Agents Chemother; 1992 May; 36(5):962-5. PubMed ID: 1510420
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetic interactions of cefprozil with food, propantheline, metoclopramide, and probenecid in healthy volunteers.
    Shukla UA; Pittman KA; Barbhaiya RH
    J Clin Pharmacol; 1992 Aug; 32(8):725-31. PubMed ID: 1487562
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of time of administration and posture on the pharmacokinetics of cefprozil.
    Shyu WC; Gleason CR; Barbhaiya RH
    Clin Pharmacokinet; 1993 Sep; 25(3):237-42. PubMed ID: 8222462
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics of cefprozil in healthy subjects and patients with renal impairment.
    Shyu WC; Pittman KA; Wilber RB; Matzke GR; Barbhaiya RH
    J Clin Pharmacol; 1991 Apr; 31(4):362-71. PubMed ID: 2037710
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multiple-dose pharmacokinetics of ceftazidime and its influence on fecal flora.
    Kemmerich B; Warns H; Lode H; Borner K; Koeppe P; Knothe H
    Antimicrob Agents Chemother; 1983 Sep; 24(3):333-8. PubMed ID: 6357074
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oral absolute bioavailability and intravenous dose-proportionality of cefprozil in humans.
    Shyu WC; Shah VR; Campbell DA; Wilber RB; Pittman KA; Barbhaiya RH
    J Clin Pharmacol; 1992 Sep; 32(9):798-803. PubMed ID: 1430299
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of quercetin on pharmacokinetics of cefprozil in Chinese-Han male volunteers.
    Jia FF; Tan ZR; McLeod HL; Chen Y; Ou-Yang DS; Zhou HH
    Xenobiotica; 2016 Oct; 46(10):896-900. PubMed ID: 26928207
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics of cefprozil in plasma and middle ear fluid: in children undergoing treatment for acute otitis media.
    Nicolau DP; Sutherland CA; Arguedas A; Dagan R; Pichichero ME
    Paediatr Drugs; 2007; 9(2):119-23. PubMed ID: 17407367
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of cefprozil and cefaclor pharmacokinetics and tissue penetration.
    Barbhaiya RH; Shukla UA; Gleason CR; Shyu WC; Wilber RB; Pittman KA
    Antimicrob Agents Chemother; 1990 Jun; 34(6):1204-9. PubMed ID: 2393282
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacology and pharmacokinetics of cefprozil.
    Barriere SL
    Clin Infect Dis; 1992 Jun; 14 Suppl 2():S184-8; discussion S195-6. PubMed ID: 1617036
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics of cefprozil in infants and children.
    Sáez-Llorens X; Shyu WC; Shelton S; Kumiesz H; Nelson J
    Antimicrob Agents Chemother; 1990 Nov; 34(11):2152-5. PubMed ID: 2073105
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics of cefprozil in healthy subjects and patients with hepatic impairment.
    Shyu WC; Wilber RB; Pittman KA; Garg DC; Barbhaiya RH
    J Clin Pharmacol; 1991 Apr; 31(4):372-6. PubMed ID: 2037711
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics of cefetamet (Ro 15-8074) and cefetamet pivoxil (Ro 15-8075) after intravenous and oral doses in humans.
    Koup JR; Dubach UC; Brandt R; Wyss R; Stoeckel K
    Antimicrob Agents Chemother; 1988 Apr; 32(4):573-9. PubMed ID: 3377466
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.